Loading…
Sterling Pharmaceutical Services, LLC, a drug manufacturing facility in Illinois, was cited for significant Current Good Manufacturing Practice (CGMP) violations that rendered their finished pharmaceutical products adulterated. The facility's deficiencies were particularly concerning because many products were ophthalmic drugs intended for use in young children, and the company was also found to be manufacturing unapproved new drugs in violation of federal regulations. The FDA inspection conducted in February 2022 identified multiple specific violations of CGMP regulations governing manufacturing, processing, packing, and holding of drug products.